Jiangsu Recbio Technology Co., Ltd. Class H · HKEX:2179

Jiangsu Recbio Technology Co., Ltd. Class H — FY2022 Earnings Presentation

28 slides from Jiangsu Recbio Technology Co., Ltd. Class H's earnings presentation, March 2023

Slide 1: Full Year 2022 Results & Corporate Update
FULL YEAR 2022 RESULTS & CORPORATE UPDATE Recbio (02179.HK) Protect Human Health with Best-in-class Vaccines March 2023 FY2022 Financial Result Presentation © 2023 Recbio. All rights reserved.
Slide 2: Disclaimer
Disclaimer Important Reminder • The information, statements and opinions set forth and/or conveyed in this presentation and accompanying discussion (collectively, the "Presentation") are for information and information purposes only and do not constitute a public offer or offer to sell or a solicita
Slide 4: Recbio Reports Full Year 2022 Results and Provides Corporate Updates
Recbio Reports Full Year 2022 Results and Provides Corporate Updates Continued Clinical Progress across Key Assets Financials at a Glance REC603 - Recombinant HPV 9-valent Vaccine R&D Expenses (k RMB) • Conducting Ph3 clinical trial with the largest sample size in China, total samplesize of 16,050 s
Slide 5: Experienced Management Team Covering the Whole Industry Chain of Innovative Vaccines
Experienced Management Team Covering the Whole Industry Chain of Innovative Vaccines Dr. Liu Yong Founder, Chairman of the Board and General Manager ✓ Postdoctoral research in basic medical sciences, China CDC ✓ 23+ years experience in the development and commercialization of innovative vaccines. Pr
Slide 6: Platform: Novel Adjuvants Benchmarking MNCs
Platform: Novel Adjuvants Benchmarking MNCs Traditional Continuing R&D of next- adjuvants FDA approved novel adjuvants for human vaccines generation novel adjuvants 2 Protein Engineering aluminum CpG BFA02 BFA03 BFA04 BFA01 6 BFA-A BFA-B ... • Structure-based immunogen design provides antigen optimi
Slide 7: Rich Vaccine Pipeline Covering Six Major Disease Areas
Rich Vaccine Pipeline Covering Six Major Disease Areas R&D status Commercial Disease Asset Type of Vaccine Adjuvant Product Right Commercialization Right Preclinical IND Filing Phase I Phase II Phase III REC603 HPV 9-valent vaccine Alum Self-developed Global Expected to submit BLA application in 202
Slide 8: Production and QC Systems Comply with Industry-leading GMP Standards
Production and QC Systems Comply with Industry-leading GMP Standards Antigen workshop GMP-standard ReCOV manufacturing facility Adjuvant Workshop HPV vaccine manufacturing facility Preparation workshop FY2022 Financial Result Presentation © 2023 Recbio. All rights reserved. 8
Slide 10: Huge HPV Vaccine Market and Limited 9-Valent Vaccine Supply
HPV Shingles Covid-19 Huge HPV Vaccine Market and Limited 9-Valent Vaccine Supply China 9-Valent HPV Vaccine Market The demand continues to expand, and domestic 9-valent HPV Ten Ministries and Commissions jointly issued the action plan: Encourage vaccine is expected to accelerate the spread of HPV v
Slide 11: REC603: Good Safety and Strong Immunogenicity in Phase I Study
HPV Shingles Covid-19 REC603: Good Safety and Strong Immunogenicity in Phase I Study Randomized, double-blinded, placebo-controlled Phase I study among healthy female subjects aged 9 to 45 years, to evaluate safety and immunogenicity of Recombinant 9-valent HPV Vaccine (REC603) Sequential Enrollment
Slide 12: REC603: Key Design of Phase III Study
HPV Shingles Covid-19 REC603: Key Design of Phase III Study Phase III Clinical Trial: Enrollment Completed Phase III clinical trial with the largest sample REC Clinical trial sites with high HPV infection rate: 603 Clinical Plans size in China: 12 sites in Henan, Shanxi and Yunnan provinces • Reach
Slide 13: WHO PQ Standard HPV Vaccine Manufacturing Site Ready by 2023
HPV Shingles Covid-19 WHO PQ Standard HPV Vaccine Manufacturing Site Ready by 2023 • Designed manufacturing capacity: 20 million doses of 9-valent HPV vaccine / year FY2022 Financial Result Presentation © 2023 Recbio. All rights reserved. 16
Slide 14: Next-Generation HPV Vaccine Candidates With New Adjuvant: REC604a, REC604b
HPV Shingles Covid-19 Next - Generation HPV Vaccine Candidates With New Adjuvant: REC604a, REC604b Next-Generation HPV Vaccines with Novel Adjuvant Build up Recbio’s Unique, Comprehensive and Highly Differentiated HPV Assets • Next-generation HPV 4-valent • Novel Adjuvant: BFA04 (benchmark AS04) REC
Slide 15: Heavy Burden of Herpes Zoster and a Promising Future for Vaccines
HPV Shingles Covid-19 Heavy Burden of Herpes Zoster and a Promising Future for Vaccines Herpes Zoster Vaccine Market Due to the growing need for prevention, the market urgently needs a better herpes Heavy disease burden with vaccination as an effective prevention zoster vaccine with good and persist
Slide 16: Vaccine Design: Recombinant Vaccine Based on Novel Liposome Adjuvant
HPV Shingles Covid-19 Vaccine Design: Recombinant Vaccine Based on Novel Liposome Adjuvant Immunogen Selection ◆ gE protein is the most abundant glycoprotein produced during viral infection ◆ gE protein mediates replication and spread of viruses ◆ gE protein contains B cell and CD4+T cell associated
Slide 17: Vaccine Design: Adjuvant Safety Already Validated Among Large Population
HPV Shingles Covid-19 Vaccine Design: Adjuvant Safety Already Validated Among Large Population • The BFA01 adjuvant benchmarks AS01B, the adjuvant used in the recombinant shingles vaccine Shingrix®, which has been approved for commercialization in more than 30 countries including the U.S., Canada, J
Slide 18: REC610: Key Design of FIH Study
HPV Shingles Covid-19 REC610: Key Design of FIH Study Randomized, Observer-Blinded, Active-Controlled, Phase I Study to Evaluate the Safety and Immunogenicity of REC610 in Healthy Adults Aged 40 Years and Older Sequential Enrollment REC610 Safety Evaluation Younger adults (M0/2） • Solicited AEs, uns
Slide 19: COVID-19 Vaccine – ReCOV: Core Advantages
HPV Shingles Covid-19 COVID-19 Vaccine – ReCOV: Core Advantages Unique NTD-RBD-Foldon Trimeric Adopts BFA03 Novel Efficacy Protein Structure Adjuvant 1 • Immunogenicity data demonstrated strong cross-neutralization against SARS-CoV-2 prototype and Omicron variants NTD: N-terminus domain • Superior t
Slide 20: ReCOV Granted EUA in Mongolia in March 2023
HPV Shingles Covid-19 ReCOV Granted EUA in Mongolia in March 2023 On March 20, 2023, Recbio announced that it was granted an Emergency Use Authorization (‘EUA’) for its two- component recombinant COVID-19 vaccine ReCOV (“ReCOV”) by Order No. A106 of the Minister of Public Health of Mongolia and a re
Slide 21: Novel Adjuvant Platform Empowers Next Generation Vaccines
Novel Adjuvant Platform Empowers Next Generation Vaccines 1 2 Benchmarking against five novel HPV Quadrivalent Vaccine adjuvants approved by FDA Novel Adjuvant COVID-19 Vaccine REC604a ReCOV (BFA03) HPV Nine-Valent Vaccine REC604b 3 4 Recombinant Adult TB Vaccine Recombinant Novel Adjuvant REC606 (B
Slide 23: Key Upcoming Catalysts and News Flow in 2023-25
Key Upcoming Catalysts and News Flow in 2023-25 Led by core products progress 2022 2023 2024 2025 HPV Vaccine Phase III follow-up Overseas BD Phase III clinical BLA Application REC603-HPV9 REC603-HPV9 interim analysis REC603 Completed Phase I trial IND Application REC603-HPV9 REC601&602-HPV2 REC604b
Slide 24: Key Takeaways
Key Takeaways Recbio, the 1st A+H Dual-listed HPV & Novel-adjuvant Innovative Vaccine Company Focusing on Major Disease Burden An innovative vaccine platform with four core technologies (novel adjuvant, protein engineering, immuo-evaluation and mRNA), with international-standard technical strengths
Slide 27: Huge HPV Vaccine Market and Limited 9-Valent Vaccine Supply
HPV Shingles Covid-19 Huge HPV Vaccine Market and Limited 9-Valent Vaccine Supply Global 9-Valent HPV Vaccine Market 9-valent HPV vaccine is considered to be the most effective HPV vaccine and the demand has far outstripped supply in global market ▪ HPV 9-valent vaccine protects up to about 90% of c
Slide 28: Drivers and Trends of the HPV Vaccine Market in China
HPV Shingles Covid-19 Drivers and Trends of the HPV Vaccine Market in China Increasing Acceptance and Vaccination Rate • Currently low awareness rate of 30%, and low full-course vaccination High Disease Burden rate of less than 1% • Only 12.9% five-year survival • COVID-19 vaccine increased general

Jiangsu Recbio Technology — FY2022 Earnings Presentation on 6ix

Jiangsu Recbio Technology Co., Ltd. Class H — FY2022 Earnings Presentation

Slide 1: Full Year 2022 Results & Corporate Update

Slide 2: Disclaimer

Slide 3: Agenda

Slide 4: Recbio Reports Full Year 2022 Results and Provides Corporate Updates

Slide 5: Experienced Management Team Covering the Whole Industry Chain of Innovative Vaccines

Slide 6: Platform: Novel Adjuvants Benchmarking MNCs

Slide 7: Rich Vaccine Pipeline Covering Six Major Disease Areas

Slide 8: Production and QC Systems Comply with Industry-leading GMP Standards

Slide 9: Agenda

Slide 10: Huge HPV Vaccine Market and Limited 9-Valent Vaccine Supply

Slide 11: REC603: Good Safety and Strong Immunogenicity in Phase I Study

Slide 12: REC603: Key Design of Phase III Study

Slide 13: WHO PQ Standard HPV Vaccine Manufacturing Site Ready by 2023

Slide 14: Next-Generation HPV Vaccine Candidates With New Adjuvant: REC604a, REC604b

Slide 15: Heavy Burden of Herpes Zoster and a Promising Future for Vaccines

Slide 16: Vaccine Design: Recombinant Vaccine Based on Novel Liposome Adjuvant

Slide 17: Vaccine Design: Adjuvant Safety Already Validated Among Large Population

Slide 18: REC610: Key Design of FIH Study

Slide 19: COVID-19 Vaccine – ReCOV: Core Advantages

Slide 20: ReCOV Granted EUA in Mongolia in March 2023

Slide 21: Novel Adjuvant Platform Empowers Next Generation Vaccines

Slide 22: Agenda

Slide 23: Key Upcoming Catalysts and News Flow in 2023-25

Slide 24: Key Takeaways

Slide 25: Agenda

Slide 26: Appendix - I HPV Vaccine Market & Driver

Slide 27: Huge HPV Vaccine Market and Limited 9-Valent Vaccine Supply

Slide 28: Drivers and Trends of the HPV Vaccine Market in China